Natriuretic peptides during the development of doxorubicin‐induced left ventricular diastolic dysfunction

Abstract. Nousiainen T, Vanninen E, Jantunen E, Puustinen J, Remes J, Rantala A, Vuolteenaho O, Hartikainen J (Kuopio University Hospital, Kuopio; Satakunta Central Hospital, Pori; University of Oulu, Oulu, Finland). Natriuretic peptides during the development of doxorubicin‐induced left ventricular diastolic dysfunction. J Intern Med 2002; 251: 228–234.

[1]  G. Baxter.  The natriuretic peptides , 2004, Basic Research in Cardiology.

[2]  M. P. van den Berg,et al.  Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Shinobu Nakamura,et al.  Brain Natriuretic Peptide Is a Predictor of Anthracycline-Induced Cardiotoxicity , 2001, Acta Haematologica.

[4]  M. Runge,et al.  Doxorubicin-Induced Cardiomyopathy , 2000 .

[5]  W. Klein,et al.  Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy. , 1999, European heart journal.

[6]  J. Hartikainen,et al.  Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non‐Hodgkin's lymphoma , 1999, European journal of haematology.

[7]  T. Helenius,et al.  Serum N-terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up in children with cancer. , 1998, Medical and pediatric oncology.

[8]  L. Ceriani,et al.  Relationship between left ventricular diastolic function and atrial natriuretic factor in never-treated mild hypertensives. , 1997, American journal of hypertension.

[9]  J. Heikkilä,et al.  Associations between atrial natriuretic peptides, echocardiographic findings and mortality in an elderly population sample , 1997, Journal of internal medicine.

[10]  A. Serafini,et al.  Review of tests for monitoring doxorubicin-induced cardiomyopathy. , 1996, Oncology.

[11]  J. Sanderson,et al.  Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. , 1996, European heart journal.

[12]  Y. Cottin,et al.  Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline? , 1996, European Journal of Nuclear Medicine.

[13]  B. Lipworth,et al.  Increased plasma levels of brain natriuretic peptide in patients with isolated diastolic dysfunction. , 1994, American heart journal.

[14]  K. Bailey,et al.  Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction , 1993, The Lancet.

[15]  H. Ruskoaho.  Atrial natriuretic peptide: synthesis, release, and metabolism. , 1992, Pharmacological reviews.

[16]  P. Koistinen,et al.  Effect of physical exercise in hypobaric conditions on atrial natriuretic peptide secretion. , 1992, The American journal of physiology.

[17]  M. Uusitupa,et al.  Left ventricular function and dimensions in newly diagnosed non-insulin-dependent diabetes mellitus. , 1992, The American journal of cardiology.

[18]  R. Schwartz,et al.  Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. , 1992, Pediatrics.

[19]  G. Pupita,et al.  High levels of plasma atrial natriuretic factor and impaired left ventricular diastolic function in hypertensives without left ventricular hypertrophy , 1992, Journal of hypertension.

[20]  J. Remes,et al.  Neuroendocrine activity in untreated heart failure. , 1991, British heart journal.

[21]  K. Inouye,et al.  Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. , 1991, The Journal of clinical investigation.

[22]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[23]  H. Pouleur,et al.  Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. , 1989, American heart journal.

[24]  P. Sager,et al.  Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. , 1987, The American journal of medicine.

[25]  J. Gierse,et al.  Proteolytic processing of atriopeptin prohormone. , 1986, Molecular pharmacology.

[26]  N. Seidah,et al.  Identification of a biologically active circulating form of rat atrial natriuretic factor. , 1985, Biochemical and biophysical research communications.

[27]  N. Ling,et al.  Atrial natriuretic polypeptides (ANP): rat atria store high molecular weight precursor but secrete processed peptides of 25-35 amino acids. , 1985, Biochemical and biophysical research communications.

[28]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[29]  C L Feldman,et al.  Assessment of Left Ventricular Ejection Fraction and Volumes by Real-time, Two-dimensional Echocardiography: A Comparison of Cineangiographic and Radionuclide Techniques , 1979, Circulation.

[30]  A. DeMaria,et al.  Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements , 1978, Circulation.

[31]  J. Mason,et al.  Anthracycline cardiomyopathy monitored by morphologic changes. , 1978, Cancer treatment reports.

[32]  P. Ghezzi,et al.  Preliminary study on behaviour of atrial natriuretic factor in anthracycline-related cardiac toxicity. , 1991, International journal of clinical pharmacology research.

[33]  N. Seidah,et al.  The propeptide Asn1-Tyr126 is the storage form of rat atrial natriuretic factor. , 1987, The Biochemical journal.